Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4521 On Other Exchanges
4521 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

kaken pharmaceutical co ltd (4521) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. It operates through two segments, Pharmaceuticals and Real Estate. The company offers pharmaceutical and medical devices products, such as Artz, an anti-osteoarthritis drug to treat knee joint pain accompanied by rheumatoid arthritis; Clenafin, a triazole compound for topical medication for onychomycosis; Seprafilm, an anti-adhesive absorbent barrier; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing drug. Its pharmaceutical and medical devices products also include Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain- and inflammation-relieving plaster; Mentax, a topical product used to treat superficial mycosis; Ebrantil, a a1 blocker to treat dysuria and hypertension; Berasus to treat pulmonary arterial hypertension; and Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery. In addition, the company provides agrochemicals, including Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. Further, it offers animal health products comprising Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Additionally, the company is developing KCB-1D for the treatment of periodontitis; KAG-308, a Phase II clinical product to treat Ulcerative colitis; BBI-4000 that is in pre-clinical stage to treat primary focal hyperhidrosis; and SI-657, which is in Phase-III clinical trials to treat Enthesopathy. It primarily focuses on fields, such as inflammation, allergies, and pain relief, as well as fungal infection. The company also rents Bunkyo Green Court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,503 Employees
Last Reported Date: 06/26/15
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2015; Provides Earnings Guidance for the Year Ending March 31, 2016

Kaken Pharmaceutical Co. Ltd. reported consolidated earnings results for the nine months ended December 31, 2015. For the year, the company reported net sales of JPY 93,889 million, operating income of JPY 20,631 million, ordinary income of JPY 20,394 million and net income of JPY 12,122 million as compared to net sales of JPY 71,155 million, operating income of JPY 16,611 million, ordinary income of JPY 16,474 million and net income of JPY 9,605 million or JPY 86.86 per basic share for the same period a year ago. Income before income taxes and minority interests was JPY 14,728 million compared to JPY 11,602 million a year ago. For the year ending March 31, 2016, the company expects net sales of JPY 14,275 million, operating income of JPY 13,077 million, ordinary income of JPY 13,445 million and net income of JPY 20,134 million.

Kaken Pharmaceutical Co. Ltd. to Report Q3, 2016 Results on Feb 05, 2016

Kaken Pharmaceutical Co. Ltd. announced that they will report Q3, 2016 results on Feb 05, 2016

Kaken Pharmaceutical Co. Ltd. Declares Second Quarter Dividend, Payable on November 30, 2015; Provides Dividend Guidance for the Full Year of 2015

Kaken Pharmaceutical Co. Ltd. declared second quarter dividend of JPY 34.00 per share compared to JPY 27.00 per share a year ago. Payable on November 30, 2015 For the full year of fiscal 2015, the company expects to pay dividend of JPY 78 against JPY 32 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4521:JP ¥6,420.00 JPY -640.00

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4521 Industry Range
Price/Earnings 12.6x
Price/Sales 2.6x
Price/Book 3.1x
Price/Cash Flow 12.4x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KAKEN PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at